White powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from the resin of the Dracaena frondosa tree.
Loureirin B is a component of traditional Chinese medicine which helps combat neurodegenerative diseases. Extracted from the red resin of Dracaena cochinchinensis S.C Chen, known as Dragon’s Blood.
After benzyl protection, 4-hydroxyacetophenone undergoes condensation with 2,4,6-trimethoxybenzaldehyde under strong base catalysis (such as sodium hydroxide) to generate the corresponding chalcone intermediate. Finally, hydrogenation is carried out at atmospheric pressure using palladium on carbon (Pd/C) as a catalyst to remove the benzyl protecting group and simultaneously reduce the chalcone double bond, yielding Loureirin B.
Loureirin B significantly improves the arrangement and deposition of collagen fibres, decreases protein levels of ColI, ColIII and α-SMA and suppresses myofibroblast differentiation and scar proliferative activity, in a rabbit ear scar model. Loureirin B effectively inhibits TGF-β1-induced upregulation of ColI, ColIII and α-SMA levels, myofibroblast differentiation and the activation of Smad2 and Smad3, in NS fibroblasts[3].
PAI-1: 26.1 μM (IC50); KATP; ERK; JNK
